Daniel A Pryor bought $289K of Enovis (ENOV)
Executed Aug 13 2025, disclosed Aug 14 2025, 1 day later.
Over the 21 trading sessions from the disclosed entry session (Aug 14 2025), the stock returned +10.9% (delay-adjusted); from the execution session (Aug 13 2025), +9.3%. Derived: entry at the session's open, exit at the close 20 sessions later.
Daniel A Pryor (EVP, Strategy & Business Dev.) filed 1 Form 4 report in the past 24 months (1 purchase, 0 sales), most often in Enovis Corporation (ENOV). Across 1 priced purchase filing, the average 21-session return was +9.3% from execution and +10.9% from disclosure (delay-adjusted; derived). The largest single filing was $289K of ENOV (10,000 sh × $28.90, as filed), executed Aug 13 2025.
Healthcare · Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and intern…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→